Medipost Co Ltd

078160

Company Profile

  • Business description

    Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.

  • Contact

    21, Daewangpangyo-ro 644
    Bundang-gu
    Gyeonggi-do
    Seongnam
    KOR

    T: +82 234656650

    http://www.medi-post.co.kr

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    334

Stocks News & Analysis

stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks

Chart of the Week: US equity market trading at an attractive discount

The latest from our Chief US Market Strategist.
stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,149.2024.100.26%
CAC 408,263.87355.134.49%
DAX 4024,080.631,159.045.06%
Dow JONES (US)47,909.921,325.462.85%
FTSE 10010,608.88260.092.51%
HKSE25,808.0085.02-0.33%
NASDAQ22,634.99617.142.80%
Nikkei 22555,861.55446.87-0.79%
NZX 50 Index13,278.4824.540.19%
S&P 5006,782.81165.962.51%
S&P/ASX 2008,949.7034.300.38%
SSE Composite Index3,965.7029.30-0.73%

Market Movers